License and Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

		Year Ended December 31,
Partner	Agreement	2020		2019		2018
Bristol-Myers Squibb	Bempegaldesleukin	$	50,000	$	—	$	1,059,768
Eli Lilly and Company	NKTR-358	1,259		7,019		11,634
Amgen, Inc.	Neulasta®	4,167		5,000		5,000
Baxalta Incorporated / Takeda	Hemophilia, including ADYNOVATE® and ADYNOVI®	346		378		20,328
Other		77		4,578		535
License, collaboration and other revenue		$	55,849	$	16,975	$	1,097,265

Changes in Deferred Revenue Balance from Collaboration Agreements

The following table presents the changes in our deferred revenue balance from our collaboration agreements during the year ended December 31, 2020 (in thousands):

	For the year ended December 31, 2020
Deferred revenue—December 31, 2019	$	8,071
Recognition of previously unearned revenue	(5,516)
Deferred revenue—December 31, 2020	$	2,555